Vijay Pande on Scaling a16z Bio & Health: Why Concentrated VC Bets Win in 2026

After deploying over $4 billion across healthcare and bio-it startups, Vijay Pande of Andreessen Horowitz is championing a refined investment thesis: fewer, higher-conviction bets.

Speaking on venture strategy in 2026, Pande explained that backing 30+ early-stage companies annually dilutes operational support in highly complex domains like AI drug discovery and clinical synth-data.

Instead, a16z Bio & Health is focusing resources on high-momentum platform companies capable of integrating wet-lab automation directly into foundation bio-models.

This strategic pivot reflects broader venture capital discipline as bio-AI startups transition from initial research proofs-of-concept to regulated commercial execution.